News

February 9, 2021
|
Category:

Dewpoint profiled in Nature review of condensate focused start-ups

A Nature review of condensate focused start-ups has described Dewpoint as the “field’s frontrunner’. The article has profiled three condensate focused biotech’s, and discusses the importance of condensate modification as the next big hope for drug discovery.

Read more on nature.com

Media Contact

media@dewpointx.com

Investor Contact

Michael Fenn, PH.D.
Head of External Innovation
Dewpoint Therapeutics
mfenn@dewpointx.com
Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
USA
© 2019-2024 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science